The Generic Pharmaceutical Association (GphA)'s 2006 Annual Policy Conference will be held at Ritz-Carlton, Washington, D.C., USA from September 19-20, 2006.
This event will provide all interested generic industry stakeholders with the latest information on issues that could impact corporate decision-making. The conference will discuss the latest legislative and policy developments, including the Prescription Drug User Fee Act, pharmaceutical pedigree, generic biopharmaceuticals and other 2007 legislative proposals.
The topic of increasing generic industry mergers and acquisitions will be discussed in a CEO panel discussion. Besides, the conference will focus on important court decisions and legal trends, including patent reform, preliminary injunctions, generic/brand settlements and forfeiture provisions.
Keynote addresses will be delivered by Bruce Downey, Chairman & CEO, Barr Pharmaceuticals, Inc., and William Marth, president & CEO, Teva Pharmaceuticals. USA Government's US Senator Orrin Hatch, (R) Utah, U.S. Representative Henry A. Waxman, (D) California, U.S. Representative Nathan Deal, (R) Georgia, Administrator Mark B. McClellan, Centres for Medicare and Medicaid Services, Commissioner Jon Leibowitz, Federal Trade Commission, Sheldon Bradshaw, Chief Counsel, Food and Drug Administration, Liz Dickinson, Associate Chief Counsel for Drugs, Food and Drug Administration etc. are also among the speakers.
The organizers informed GphA's Fall Technical Conference, 2006 will be held at Marriott Bethesda North Hotel and Conference Centre, North Bethesda, Maryland on October 18-19, 2006, with a Pre-Conference Project Manager Workshop from October 17, 2006.
The GPhA Annual Fall Technical Conference is the premier science and regulatory meeting for the US generic pharmaceutical industry. More than a dozen top officials from FDA will present the latest technical and regulatory information. The conference addresses key current regulatory and technical issues like regulatory developments including draft regulations, filing issues and legal updates; chemistry manufacturing and controls topics, Question-based Reviews, Drug Master Files, and emerging issues; industry trends, including progress in ANDA reviews, bioequivalence, bioanalytical inspections and compliance activities. For the first time, the organisers have designed two concurrent breakout sessions tailored to the needs of industry professionals on 'Sterile Products' and another on 'Clinical End Point Studies/Protocols'.
GPhA represents the manufacturers and distributors of finished generic pharmaceutical products, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic pharmaceutical industry.